Mukherjee, Nabanita
Katsnelson, Elizabeth
Brunetti, Tonya M.
Michel, Kylie
Couts, Kasey L.
Lambert, Karoline A.
Robinson, William A.
McCarter, Martin D.
Norris, David A.
Tobin, Richard P. http://orcid.org/0000-0003-3890-4534
Shellman, Yiqun G. http://orcid.org/0000-0003-0598-5753
Funding for this research was provided by:
Cancer League of Colorado
U.S. Department of Health & Human Services | NIH | Center for Information Technology (R01AR074420)
Department of Veterans Affairs | James A. Haley Veterans' Hospital (BX000141, BX000141)
Colorado University | Cancer Center, University of Colorado (P30CA046934)
SPARK|REACH University of Colorado
Department of Veterans Affairs | James A. Haley Veterans' Hospital
Article History
Received: 4 October 2023
Revised: 26 January 2024
Accepted: 30 January 2024
First Online: 8 March 2024
Competing interests
: DAN, NM, MDM, RPT, and YGS have intellectual property related to the use of BH3 mimetics in cancer. All other authors have no conflicts of interest to declare.
: All patient studies were conducted in accordance with the Declaration of Helsinki, Belmont Report, and U.S Common Rule. All patients were consented under approval from the Colorado Institutional Review Board (COMIRB #05-0309 and #17-2159) and provided written consent for the utilization of samples for data collection and publication. All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Colorado Denver (protocol #318).